Literature DB >> 31138026

Evaluation of lymphatic filariasis in endemic area of Brazil where mass drug administration is not required.

Ellyda Silva1, Amanda Xavier2, Elis Silva1, Walter Barbosa Júnior1, Abraham Rocha3,4, Vania Freitas5, Paula Oliveira3, Ana Maria Aguiar-Santos3, Cristine Bonfim6,7, Zulma Medeiros1,2,3.   

Abstract

Mass drug administration (MDA) is the main counter-transmission strategy of the Global Programme to Eliminate Lymphatic Filariasis. In endemic countries, there are areas where MDA is not required. However, there is no standard approach in these areas, and studies are important to evaluate the epidemiological status. This study aimed to investigate lymphatic filariasis and strategies developed for its control in an area where MDA is not required. Together with the 2018 morbidity evaluation, a survey was conducted using point-of-care immunochromatographic test-AD12 tests for diagnostic screening in an area where MDA is not required. The methodology also included desk research based on Health Department reports of the control activities for lymphatic filariasis during 2003-2016. Among the 934 cases investigated in 2018, there was a 0.64% prevalence of circulating filarial antigen positive, comprising five adults and one 2-year-old child. Six patients aged 39-63 years had filarial disease. Fourteen surveys have already been conducted as control activities, and since 2009, there have been no positive cases. This study showed that the prevalence of antigenemia decreased from 2.97% in 2003 to 0.64% in 2018. Moreover, the transmission of filariasis infection was under control in this area. Our study provides insights into the surveillance phase by identifying areas of low transmission and where MDA is not required. Although we have not identified cases of filarial infection, there is a need to provide services that will provide assist those already affected with morbidity and help reduce and prevent disability.

Entities:  

Keywords:  Elimination; ICT card; Lymphatic filariasis; Surveillance; Wuchereria bancrofti; mass drug administration

Mesh:

Substances:

Year:  2019        PMID: 31138026      PMCID: PMC6586090          DOI: 10.1080/20477724.2019.1623546

Source DB:  PubMed          Journal:  Pathog Glob Health        ISSN: 2047-7724            Impact factor:   3.735


  33 in total

1.  A highly specific and sensitive monoclonal antibody-based ELISA for the detection of circulating antigen in bancroftian filariasis.

Authors:  S J More; D B Copeman
Journal:  Trop Med Parasitol       Date:  1990-12

2.  A socioenvironmental composite index as a tool for identifying urban areas at risk of lymphatic filariasis.

Authors:  C Bonfim; M J E Netto; D Pedroza; J L Portugal; Z Medeiros
Journal:  Trop Med Int Health       Date:  2009-07-17       Impact factor: 2.622

3.  Studies on the periodicity and intravascular distribution of Wuchereria bancrofti microfilariae in paired samples of capillary and venous blood from Recife, Brazil.

Authors:  G Dreyer; A Pimentael; Z Medeiros; F Béliz; I Moura; A Coutinho; L D de Andrade; A Rocha; L M da Silva; W F Piessens
Journal:  Trop Med Int Health       Date:  1996-04       Impact factor: 2.622

4.  Mapping of Wuchereria bancrofti infection in children and adolescents in an endemic area of Brazil.

Authors:  Eduardo Brandão; Cristine Bonfim; Danielle Cabral; José Lancart Lima; Ana Maria Aguiar-Santos; Amélia Maciel; Zulma Medeiros
Journal:  Acta Trop       Date:  2011-06-24       Impact factor: 3.112

5.  Bancroftian filariasis: a comparison of microfilariae counting techniques using counting chamber, standard slide and membrane (nuclepore) filtration.

Authors:  J E McMahon; T F Marshall; J P Vaughan; D E Abaru
Journal:  Ann Trop Med Parasitol       Date:  1979-10

6.  Global programme to eliminate lymphatic filariasis: progress report, 2016.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2017-10-06

7.  Lymphatic filariasis in Brazilian urban area (Maceió, Alagoas).

Authors:  G Fontes; E M Rocha; A C Brito; C M Antunes
Journal:  Mem Inst Oswaldo Cruz       Date:  1998 Nov-Dec       Impact factor: 2.743

8.  Surveillance for lymphatic filariasis after stopping mass drug administration in endemic districts of Togo, 2010-2015.

Authors:  Monique Ameyo Dorkenoo; Rachel Bronzan; Degninou Yehadji; Mawèke Tchalim; Kossi Yakpa; Santrao Etassoli; Poukpessi Adjeloh; Issaka Maman; Yao Sodahlon
Journal:  Parasit Vectors       Date:  2018-04-16       Impact factor: 3.876

9.  Integrated risk mapping and landscape characterisation of lymphatic filariasis and loiasis in South West Nigeria.

Authors:  Tara A Brant; Patricia N Okorie; Olushola Ogunmola; Nureni Bolaji Ojeyode; S B Fatunade; Emmanuel Davies; Yisa Saka; Michelle C Stanton; David H Molyneux; J Russell Stothard; Louise A Kelly-Hope
Journal:  Parasite Epidemiol Control       Date:  2017-12-28

10.  Identifying residual transmission of lymphatic filariasis after mass drug administration: Comparing school-based versus community-based surveillance - American Samoa, 2016.

Authors:  Meru Sheel; Sarah Sheridan; Katherine Gass; Kimberly Won; Saipale Fuimaono; Martyn Kirk; Amor Gonzales; Shannon M Hedtke; Patricia M Graves; Colleen L Lau
Journal:  PLoS Negl Trop Dis       Date:  2018-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.